NCT00394212

Brief Summary

It is estimated that up to 20% of patients who have Roux-en-Y Gastric Bypass (RYGB) surgery will not meet their weight loss goal, or may even regain some of the weight they initially lost. One possible explanation is that the opening between the stomach pouch and the intestine becomes stretched. If this opening becomes too wide, food may be able to pass from the stomach to the intestine too quickly - causing patients to feel less full after eating. For some patients, doctors may recommend additional invasive surgery to tighten the opening between the stomach pouch and the small intestine. Although this may help patients resume their weight loss, the risk of complications during a second surgical procedure is significantly higher than the risk during the original gastric bypass. The purpose of this study is to evaluate an incisionless procedure for patients who have either had inadequate weight loss or have regained weight following gastric bypass. The procedure is designed to tighten the opening between the stomach pouch and the small intestine, which may slow down the passage of food to help patients feel full longer after eating.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at below P25 for phase_3 obesity

Timeline
Completed

Started Nov 2006

Typical duration for phase_3 obesity

Geographic Reach
1 country

10 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 31, 2006

Completed
1 day until next milestone

Study Start

First participant enrolled

November 1, 2006

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
3.5 years until next milestone

Results Posted

Study results publicly available

November 7, 2012

Completed
Last Updated

September 21, 2016

Status Verified

October 1, 2012

Enrollment Period

1.8 years

First QC Date

October 27, 2006

Results QC Date

August 3, 2011

Last Update Submit

August 12, 2016

Conditions

Keywords

Weight LossTransoral SuturingDilated gastrojejunostomyInadequate weight loss following primary RYGB

Outcome Measures

Primary Outcomes (1)

  • Weight Loss (%)

    Percent Weight Loss is computed as \[(Baseline weight - 6 mo. weight) / Baseline weight\] \* 100

    6 months

Secondary Outcomes (3)

  • Subjects Achieving 15% Excess Weight Loss (EWL)

    6 months

  • Subjects Achieving Weight Stabilization at 6 Months

    6 months

  • Subjects Achieving 20% Excess Weight Loss at 6 Months

    6 months

Study Arms (2)

1

EXPERIMENTAL

Transoral suturing of the dilated gastrojejunostomy

Device: Transoral Suturing

2

SHAM COMPARATOR

Sham Endoscopy (suturing not performed)

Other: Sham Endoscopy

Interventions

suturing of anastomosis

1

suturing not performed

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • months post primary RYGB with inadequate weight loss or weight regain
  • BMI \>30 and ≤ 50
  • Dilated gastrojejunal anastomosis
  • Successfully completes screening process
  • Signed consent

You may not qualify if:

  • Recently quit smoking or plan to quit within the next year
  • Pregnant or planning to become pregnant over the course of the next 9 months
  • Mallampati score of 4
  • Serious systemic disease or active disease of the gastrointestinal tract
  • Gastric pouch abnormalities
  • Significant movement limitations
  • Use of weight-promoting or weight-reduction drugs during study period
  • Severe eating disorders
  • Uncontrolled depression or psychoses
  • Ongoing severe complication resulting from initial RYGB or other condition that in the investigators' assessment would make the patient an unsuitable candidate for the study procedure
  • History of significant cardiovascular, cerebrovascular or pulmonary disease
  • Not a candidate for conscious or general sedation
  • Anticoagulant therapies
  • Active substance abuse
  • Life expectancy \< 1 year
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Unknown Facility

Denver, Colorado, United States

Location

Unknown Facility

Baltimore, Maryland, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Lebanon, New Hampshire, United States

Location

Unknown Facility

New York, New York, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

Milwaukee, Wisconsin, United States

Location

Related Publications (1)

  • Thompson CC, Chand B, Chen YK, DeMarco DC, Miller L, Schweitzer M, Rothstein RI, Lautz DB, Slattery J, Ryan MB, Brethauer S, Schauer P, Mitchell MC, Starpoli A, Haber GB, Catalano MF, Edmundowicz S, Fagnant AM, Kaplan LM, Roslin MS. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery. Gastroenterology. 2013 Jul;145(1):129-137.e3. doi: 10.1053/j.gastro.2013.04.002. Epub 2013 Apr 5.

MeSH Terms

Conditions

ObesityWeight Loss

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsBody Weight Changes

Limitations and Caveats

Limitations of this study are that study enrollment was prematurely discontinued; therefore the study was underpowered for the analysis of both the primary and secondary effectiveness endpoints.

Results Point of Contact

Title
Dawn Heimer, Clinical Research
Organization
Davol Inc., Subsidiary of C.R. Bard

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2006

First Posted

October 31, 2006

Study Start

November 1, 2006

Primary Completion

September 1, 2008

Study Completion

May 1, 2009

Last Updated

September 21, 2016

Results First Posted

November 7, 2012

Record last verified: 2012-10

Locations